NICE publishes final no for Roche's Avastin for metastatic bowel cancer
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has today published final guidance not to recommend Roche's Avastin (bevacizumab), in combination with chemotherapy (oxaliplatin and either 5-fluorouracil plus folinic acid or capecitabine), for treating patients with metastatic colorectal cancer. The institute had doubts about whether the drug's benefits justified its high cost.